Evoke Pharma Inc (EVOK)
4.58
+0.21
(+4.91%)
USD |
NASDAQ |
Nov 15, 16:00
4.51
-0.07
(-1.53%)
After-Hours: 20:00
Evoke Pharma Research and Development Expense (TTM): 0.0389M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.0389M |
| June 30, 2024 | 0.0272M |
| March 31, 2024 | 0.1196M |
| December 31, 2023 | 0.1819M |
| September 30, 2023 | 0.1866M |
| June 30, 2023 | 0.2269M |
| March 31, 2023 | 0.3261M |
| December 31, 2022 | 0.3008M |
| September 30, 2022 | 0.3093M |
| June 30, 2022 | 0.3506M |
| March 31, 2022 | 0.3544M |
| December 31, 2021 | 0.5905M |
| September 30, 2021 | 0.6586M |
| June 30, 2021 | 0.7819M |
| March 31, 2021 | 6.369M |
| December 31, 2020 | 6.555M |
| September 30, 2020 | 7.092M |
| June 30, 2020 | 7.710M |
| March 31, 2020 | 3.133M |
| December 31, 2019 | 3.416M |
| September 30, 2019 | 3.470M |
| June 30, 2019 | 3.273M |
| March 31, 2019 | 3.456M |
| December 31, 2018 | 4.095M |
| Date | Value |
|---|---|
| September 30, 2018 | 5.031M |
| June 30, 2018 | 7.123M |
| March 31, 2018 | 7.752M |
| December 31, 2017 | 7.138M |
| September 30, 2017 | 7.008M |
| June 30, 2017 | 5.630M |
| March 31, 2017 | 5.707M |
| December 31, 2016 | 6.952M |
| September 30, 2016 | 7.158M |
| June 30, 2016 | 7.656M |
| March 31, 2016 | 7.749M |
| December 31, 2015 | 8.154M |
| September 30, 2015 | 8.622M |
| June 30, 2015 | 9.873M |
| March 31, 2015 | 10.56M |
| December 31, 2014 | 9.992M |
| September 30, 2014 | 8.452M |
| June 30, 2014 | 5.442M |
| March 31, 2014 | 2.698M |
| December 31, 2013 | 0.957M |
| September 30, 2013 | 0.6389M |
| June 30, 2013 | 0.8972M |
| March 31, 2013 | 0.9793M |
| December 31, 2012 | 1.166M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
0.0272M
Minimum
Jun 2024
7.710M
Maximum
Jun 2020
1.936M
Average
0.3525M
Median
Research and Development Expense (TTM) Benchmarks
| Repligen Corp | 41.81M |
| Eli Lilly and Co | 10.53B |
| MEI Pharma Inc | 16.56M |
| Revance Therapeutics Inc | 77.24M |
| NovaBay Pharmaceuticals Inc | 0.064M |